The DEI Task Force held a Corporate Member Roundtable on November 12, 2022 with key stakeholders including Industry (pharmaceutical and biotech companies), the FDA and SITC leadership. Organized by Leisha Emens, MD, PhD, Padmanee Sharma, MD, PhD, and John H. Stewart, IV, MD, MBA, FACS, the roundtable aimed to create a discussion with the FDA Guidance on diversity in clinical trial enrollment, elucidate questions and challenges key stakeholders have in implementing the guidance, and facilitate a conversation with these key stakeholders to provide clarity and direction.
To build on the learnings from the November 2022 Roundtable, the Organizers will host a virtual Roundtable on Diversity in Clinical Trial Enrollment on July 25, 2023. The goal of the virtual Roundtable is to walk away with recommendations for specific actions each stakeholder in the clinical trial ecosystem can take to positively impact diversity in clinical trial enrollment. Representatives from each stakeholder group will participate in the roundtable, which will consist of a series of presentations and panels that highlight success stories and lessons learned in addressing implicit bias challenges, creating patient and community engagement and optimizing trial designs and operations that facilitate access to clinical trials for patients of diverse backgrounds. By enabling a conversation across stakeholders, SITC aims to carve a roadmap for next steps each stakeholder group can take to increase diversity in all immuno-oncology clinical trials.